Compositions and methods for treating diabetes
Disclosed herein are compositions and methods for treating diabetes wherein the compositions comprise GLP-1 agonists. The disclosed compositions are also effective for reducing body weight and improving triglyceride and cholesterol levels. Disclosed herein are methods for treating type-2 diabetes in a subject, for lowering a subject's A1C, for lowering the body mass of a subject, and for regulating the incretin hormone levels of a subject.
1 . A method for treating type-2 diabetes in a subject comprising administering to a subject in need a composition comprising:
a) from about 0.5% to about 20% by weight of one or more GLP-1 agonists;
b) from about 0.5% to about 40% by weight of olive oil;
c) from about 1.5% to about 65% by weight of a bile salt extract;
d) from about 35% to about 65% by weight of sodium bicarbonate; and
e) from about 15% to about 85% by weight of one or more carriers.
2 . The method according to claim 1 , wherein the GLP-1 agonist is chosen from dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide, or mixtures thereof.
3 . The method according to claim 1 , wherein the GLP-1 agonist is liraglutide.
4 . The method according to claim 1 , wherein the GLP-1 agonist is semaglutide.
5 . The method according to claim 1 , wherein the bile salt extract contains from about 45% to about 55% by weight of a bile salt selected from the group consisting of cholic acid, deoxycholic acid, taurocholate, and glycocholic acid, or a mixture thereof.
6 . The composition according to claim 1 , wherein the bile salt is deoxycholic acid.
7 . The composition according to claim 1 , wherein the one or more carriers are chosen from sodium N-[8-(2-hydroxybenzoyl)amino] caprylate (SNAC), gum Arabic, inulin, mannitol, silicon dioxide, colloidal silicon dioxide, microcrystalline cellulose, D-lactose monohydrate, tapioca starch, tapioca flour, and quillaia , or mixtures thereof.
8 . The composition according to claim 1 , wherein the carrier is chosen from mannitol, and colloidal silicon dioxide, or mixtures thereof.
9 . A method for treating type-2 diabetes in a subject comprising administering to a subject in need a composition comprising:
a) from about 0.2 mg to about 25 mg of one or more GLP-1 agonists chosen from dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide, or mixtures thereof;
b) from about 0.4 mg to about 50 mg of olive oil;
c) from about 0.05 mg to about 5 mg of a bile salt extract wherein the bile salts are an extract containing from about 45% to about 55% by weight of cholic acid, deoxycholic acid, taurocholate, and glycocholic acid, or mixtures thereof;
d) from about 1 mg to about 460 mg of sodium bicarbonate; and
e) from about 3 mg to about 480 mg of one or more carriers chosen from sodium N-[8-(2-hydroxybenzoyl)amino] caprylate (SNAC) gum Arabic, inulin, mannitol, silicon dioxide, colloidal silicon dioxide, microcrystalline cellulose, D-lactose monohydrate, tapioca starch, tapioca flour, and quillaia , or mixtures thereof.
10 . The method according to claim 9 , wherein the GLP-1 agonist is chosen from dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide, or mixtures thereof.
11 . The method according to claim 9 , wherein the GLP-1 agonist is liraglutide.
12 . The method according to claim 9 , wherein the GLP-1 agonist is semaglutide.
13 . The method according to claim 9 , wherein the bile salt extract contains from about 45% to about 55% by weight of a bile salt selected from the group consisting of cholic acid, deoxycholic acid, taurocholate, and glycocholic acid, or a mixture thereof.
14 . The method according to claim 9 , wherein the bile salt is deoxycholic acid.
15 . The method according to claim 9 , wherein the one or more carriers are chosen from sodium N-[8-(2-hydroxybenzoyl)amino] caprylate (SNAC), gum Arabic, inulin, mannitol, silicon dioxide, colloidal silicon dioxide, microcrystalline cellulose, D-lactose monohydrate, tapioca starch, tapioca flour, and quillaia , or mixtures thereof.
16 . The method according to claim 9 , wherein the carrier is chosen from mannitol, and colloidal silicon dioxide, or mixtures thereof.